文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤患者自体造血干细胞移植后达雷妥尤单抗维持治疗

[Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

回顾性分析15例新诊断多发性骨髓瘤患者自体造血干细胞移植后接受达雷妥尤单抗维持治疗的资料,中位维持6个月、中位输注12次;严格意义的完全缓解率由40%升至60%,3级肺炎发生5例(33.33%),1年总生存率93.33%。

要点

  • 达雷妥尤单抗维持使严格意义的完全缓解率由40%升至60%。
  • 非血液学不良事件以输注相关反应(46.67%)和3级肺炎(33.33%)为主。
  • 5例肺炎均为达雷妥尤单抗初治者,中位输注8次时发生。

核心结论

  • 达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植后维持治疗安全有效,不良事件可控。
  • 最常见的非血液学不良事件为3级肺炎,减少维持治疗前8周每周一次给药频次可能降低肺炎发生率。

研究设计与样本

  • 回顾性分析2022年5月1日至2023年6月30日期间解放军总医院第五医学中心血液病医学部淋巴瘤-浆细胞疾病专科15例新诊断多发性骨髓瘤患者自体造血干细胞移植后接受达雷妥尤单抗维持治疗的临床资料、血液学及肾脏疗效与安全性。
  • 15例患者中男11例、女4例,中位年龄58(41~72)岁;13例于诱导治疗及自体造血干细胞移植阶段均未使用达雷妥尤单抗,6例伴肾损害,9例遗传学高危。

主要发现

  • 达雷妥尤单抗维持治疗中位时间6(1.5~12)个月,中位输注次数12(6~17)次。
  • 15例均可评估疗效,严格意义的完全缓解率由40%增加至60%。
  • 6例伴肾损害患者的肾脏缓解率由16.67%提升至33.33%。
  • 血液学3级以上不良事件主要为淋巴细胞减少(26.67%,4/15),非血液学不良事件主要为输注相关反应(46.67%,7/15)及3级肺炎(33.33%,5/15)。
  • 5例(38.46%,5/13)发生肺炎者均为达雷妥尤单抗初治者,发生时间在中位输注8(6~10)次,其中3例肺炎为肺间质改变、甲泼尼龙治疗有效;中位随访12(7~13)个月,1例死亡(与达雷妥尤单抗治疗无关),1年总生存率93.33%。

临床怎么用

  • 作者认为达雷妥尤单抗可作为新诊断多发性骨髓瘤患者自体造血干细胞移植后的维持治疗,不良事件可控。
  • 作者提出减少维持治疗期间前8周每周一次给药频次可能使肺炎发生率下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to evaluate the efficacy and safety of daratumumab as a maintenance treatment after autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with newly diagnosed multiple myeloma (NDMM) . Methods: The clinical data, hematological and renal response, and safety of 15 post-transplant patients with NDMM who had received daratumumab maintenance between May 1, 2022 and June 30, 2023 were retrospectively analyzed. Results: Fifteen patients (11 males and 4 females) with a median age of 58 (41-72) years were included. Thirteen patients did not receive daratumumab during induction therapy and auto-HSCT, 6 patients had renal impairment, and nine patients had high-risk cytogenetics. The median infusion of daratumumab was 12 (6-17) times, and the median duration of maintenance was 6 (1.5-12) months. The treatment efficacy was evaluated in all 15 patients, and daratumumab maintenance therapy increased the rate of stringent complete response from 40% to 60%. The renal response rate and median estimated glomerular filtration rate of six patients with RI-NDMM were also improved. During daratumumab maintenance therapy, the most common hematological grade 3 adverse event (AE) was lymphopenia [4 of 15 patients (26.67%) ], whereas the most common nonhematologic AEs were infusion-related reactions [7 of 15 patients (46.67%) ] and grade 3 pneumonia [5 of 15 patients (33.33%) ]. The five patients with pneumonia were daratumumab naive [5 of 13 patients (38.46%) ], with a median of 8 (6-10) infusions. Among them, the chest computed tomography of three patients showed interstitial infiltrates, and treatment with methylprednisolone was effective. With a median follow-up of 12 months, the 1-year overall survival rate was 93.33%, and only one patient died (which was not related to daratumumab treatment) . Conclusions: Daratumumab was safe and effective as a maintenance agent for post-auto-HSCT patients with NDMM, and AEs were controllable. The most common nonhematologic AE was grade 3 pneumonia, and a less dose-intense maintenance regimen for the first 8 weeks could reduce the incidence of pneumonia. 目的: 探讨新诊断多发性骨髓瘤(NDMM)患者自体造血干细胞移植(auto-HSCT)后达雷妥尤单抗维持治疗的疗效及安全性。 方法: 回顾性分析2022年5月1日至2023年6月30日期间解放军总医院第五医学中心血液病医学部淋巴瘤-浆细胞疾病专科的15例NDMM患者auto-HSCT后接受达雷妥尤单抗维持治疗的临床资料、血液学及肾脏疗效、安全性。 结果: 15例患者中男11例,女4例,中位年龄58(41~72)岁;其中13例患者于诱导治疗及auto-HSCT阶段均未使用达雷妥尤单抗,6例伴有肾损害,9例遗传学高危。达雷妥尤单抗维持治疗的中位时间为6(1.5~12)个月,中位输注次数12(6~17)次。15例患者均可评估疗效,达雷妥尤单抗维持治疗使缓解深度增加,血液学严格意义的完全缓解率(sCR)由40%增加至60%;6例伴肾损害患者的肾脏缓解率由16.67%提升至33.33%。血液学3级以上不良事件(AE)主要为淋巴细胞减少(26.67%,4/15),非血液学AE主要为输注相关反应(46.67%,7/15)及3级肺炎(33.33%,5/15)。5例(38.46%,5/13)发生肺炎的患者均为达雷妥尤单抗初治者,发生时间在中位输注8(6~10)次,3例肺炎为肺间质改变,甲泼尼龙治疗有效。中位随访时间为12(7~13)个月,1例死亡(与达雷妥尤单抗治疗无关),1年总生存率为93.33%。 结论: 达雷妥尤单抗用于NDMM患者auto-HSCT后维持治疗可提高血液学及肾脏缓解率,且不良反应可控。主要的AE是3级肺炎,减少维持治疗期间前8周每周一次给药频次可能使肺炎发生率下降。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ma Y, Xiao XB, Chen XL, et al. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38503525. doi:10.3760/cma.j.issn.0253-2727.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。